Benda Increases Ownership of Cancer Gene Therapy Drug


Benda Increases Ownership of Cancer Gene Therapy Drug

Related Stocks: BPMA.OB ChinaBio Today submits: Benda Pharma (BPMA.OB) incrementally increased its ownership of Gendicine, the first gene therapy for cancer, by buying another 2.56% of the stock in the maker of Gendicine, SiBiono. With this latest purchase, Benda now owns 60.13% of the total number of outstanding SiBiono shares. Complete Story »

You might be interested in these entries too:

Introgen Hints At Cancer Gene Therapy Lawsuit Against Benda

Related Stocks: BPMA.OB, INGN ChinaBio Today submits: A Washington Post article (see story), published...

Benda Pharma Offers First Gene Therapy For Cancer In The World

Related Stocks: BPMA.OB ChinaBio Today submits: On May 21, Benda Pharma (BPMA.OB) reported revenue of...

Responses to 'Benda Increases Ownership of Cancer Gene Therapy Drug'


  1. No Comments

Leave a Reply





eXTReMe Tracker